in North America is expected to drive growth of the market over the forecast period. For
instance, in December 2017, Pfizer, Inc. received the U.S. FDA approval for second biosimilar,
Ifixi to Janssen’s blockbuster drug Remicade to treat rheumatoid arthritis.
Request For Customization of Research Report @
https://www.coherentmarketinsights.com/insight/request-customization/1769
Competitive Landscape
Key players operating in the global remicade biosimilar market include Janssen Biotech, Inc.,
Merck and Company, Inc., Alvogen, Pfizer, Inc., Celltrion, Nippon Kayaku, Napp
Pharmaceuticals, and others. Market players are focused on introducing maximum number of
biosimilar for multiple indications to retain their position in the global market. For instance, in
July 2017, Merck & Company, Inc. in collaboration with Samsung Bioepis introduced Renflexis
(infliximab-abda), a biosimilar to Remicade for the treatment of moderate to severe Crohn’s
disease, active ulcerative colitis, rheumatoid arthritis, and other few disease indications.
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-
ready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com